文献速递淋巴瘤造血干细胞移植与细胞治疗白血病

慢性活动性EB病毒病:分子发病机制、演变概念与新兴治疗

Chronic active Epstein-Barr virus disease: molecular pathogenesis, evolving concepts, and emerging therapies.
PubMed 文献 · Blood · 2026-01-01

本文综述慢性活动性EB病毒(CAEBV)病的分子发病机制、诊断框架演变及新兴治疗策略,指出该病为T/NK细胞淋巴增殖性疾病,造血干细胞移植是唯一治愈手段,但移植相关死亡与复发仍是挑战,需优化预处理及移植前疾病控制。

要点

  • CAEBV为T/NK细胞淋巴增殖性疾病,亚洲外常被低估。
  • 突变EBV感染骨髓造血干/淋巴祖细胞,建立潜伏感染。
  • HSCT是唯一治愈手段,但移植相关死亡与复发需优化。

核心结论

  • CAEBV病为少见且常致死的T/NK细胞淋巴增殖性疾病,2022年国际共识分类与第五版WHO淋巴瘤分类已整合其诊断框架。

研究设计与样本

  • 本文为综述,回顾分子与免疫病理研究进展及2022年国际共识分类和第五版WHO淋巴瘤分类。

主要发现

  • 突变EBV感染骨髓造血干或淋巴祖细胞,潜伏感染随分化持续存在。
  • 感染淋巴细胞发生克隆扩增、免疫逃逸及遗传与表观遗传改变,导致系统性CAEBV病。
  • 部分病例可转化为EBV阳性淋巴瘤或白血病。
  • 亚洲与非亚洲队列存在地理差异。
  • 诊断受限于缺乏标准化且可商用的检测感染细胞亚群的方法。

关键数值与推荐

  • 造血干细胞移植仍是唯一治愈选择。
  • 移植相关死亡、复发及成人起病预后不佳需优化预处理与移植前疾病控制。

临床怎么用

  • 血液科医生应提高对CAEBV病的全球认识,关注其与EBV相关噬血细胞性淋巴组织细胞增生症及EBV阳性淋巴瘤/白血病的鉴别诊断。
  • 对疑似CAEBV病患者,应评估感染细胞亚群,但需注意缺乏标准化商用检测。
  • HSCT为治愈手段,需优化预处理方案及移植前疾病控制以改善结局。

局限性

  • 诊断仍受限于缺乏标准化和商用可及的检测感染细胞亚群的方法。
  • 移植相关死亡、复发及成人起病预后不佳。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic active Epstein-Barr virus (EBV; CAEBV) disease is an uncommon, often lethal T and/or natural killer (T/NK)-cell lymphoproliferative disorder that remains underrecognized outside Asia. Recent advances in molecular and immunopathologic studies, together with the 2022 International Consensus Classification and the fifth World Health Organization lymphoma classification, have consolidated the disease concept and diagnostic framework. Recent studies support a model in which mutated EBV infects hematopoietic stem or lymphoid progenitor cells in the bone marrow, establishing latent infection that persists as these progenitors differentiate into T/NK cells. The infected lymphocytes subsequently undergo clonal expansion, immune evasion, and progressive accumulation of genetic and epigenetic alterations, giving rise to systemic CAEBV disease and, in some cases, transformation into EBV-positive lymphomas or leukemias. We review the clinical spectrum and differential diagnosis in relation to EBV-associated hemophagocytic lymphohistiocytosis and EBV-positive lymphomas or leukemias and highlight geographic differences between Asian and non-Asian cohorts. Despite progress, diagnosis remains hampered by the lack of standardized and commercially available assays to identify infected cell subsets. Hematopoietic stem cell transplantation remains the only curative option; however, transplant-related mortality, relapse, and suboptimal outcomes in adult-onset disease underscore the need for optimized conditioning and pretransplant disease control. We review emerging therapeutic strategies, including programmed cell death 1 blockade, JAK inhibition, and EBV-specific cytotoxic T-lymphocyte therapy, and outline priorities for prospective international trials. This review aims to raise global awareness among hematologists and foster collaborative studies to improve outcomes for patients with CAEBV disease.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Kimura H, Cohen JI. Chronic active Epstein-Barr virus disease: molecular pathogenesis, evolving concepts, and emerging therapies. Blood. 2026. PMID: 41490284. doi:10.1182/blood.2025032277

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。